Today is Rare Disease Day!

Lupus is a rare disease in Europe, although for those living with it, it doesn’t feel rare at all!

There are estimated to be less than five in 10,000 people in Europe who are living with lupus. Having a rare disease means that most people around you don’t have any idea what you are going through.

 

(Positive aspect of COVID and LOCKDOWN?)

 

Up until a year ago, living with lupus meant for some, living in fear and isolation. Some lupus patients take medication that suppresses their immune system to treat their lupus, but this can make people susceptible to infections. Lupus patients often live with the threat of another bug, another flare, another complication and never know what tomorrow might bring.  But today, there’s a new feeling almost of relief. People with lupus do not feel alone anymore!

 

Living in lockdown, with the threat of COVID-19 just outside the door, has brought up feelings of isolation and of being afraid of an invisible enemy for everyone. And while that is horrible and we wish it would stop as soon as possible for people everywhere, it is what some people with lupus may experience all the time. So today when we go out, masked, gloved, with our bottle of sanitising gel, no-one looks at us weirdly. When we avoid parties, or crowds, … for the first time ever we don’t have to explain or justify our behaviour.

 

Surprisingly, there have been positive aspects of this pandemic: the generalisation of remote working, telemedicine becoming a reality, remote ordering of medicines, more awareness of the effects of chronic diseases because of the awareness around “long covid” effects!  Perhaps you have some other examples?  Let’s make sure we are very clear about how much we appreciate those developments.  As lockdowns end and we push COVID to the back of our minds, let’s not forget the lessons we all learned during this time. Let’s all use this experience as a starting point for an ongoing conversation with your friends, your families, your healthcare workers, with society at large.  Let’s all discuss how to keep those improvements, while working together to end the isolation people with rare diseases often feel.

 

(LUPUS AND COVID VACCINES)

One step to getting out of lockdown is the COVID19 vaccination.  SLEuro (The European Lupus Society is a community of clinicians and researchers interested in SLE and related syndromes) has released a very useful Q&A document on the Covid vaccine for patients with SLE.  You can find it here: https://sleuro.org/sars-cov-2/

 

A lot of lupus patients around Europe have been vaccinated already, but many have not yet been offered a vaccine.  Each country has its own vaccination priority lists. Lupus gives automatic priority in some EU countries, not in others. What is the situation in your country? What are things like for you? Have you been vaccinated? Let us know by commenting under this post on our Facebook page and on Twitter!

 

(LUPUS RARE DISEASE)

Today is Rare Disease day. We should all be aware of two significant actors that help the rare disease community raise their voices in Europe: Orphanet and Eurordis

Orphanet is the portal for rare diseases and orphan drugs, a unique resource, gathering and improving knowledge on rare diseases so as to improve the diagnosis, care and treatment of patients with rare diseases. https://www.orpha.net/

 

EURORDIS is a non-governmental patient-driven alliance of patient organisations representing 956 rare disease patient organisations in 73 countries. https://www.eurordis.org/

Have a quick look on their websites and see what they are fighting for and doing for you!

 

(RARE 2030 RECOMMENDATIONS)

This week, the recommendations from the Rare2030 foresight study were released:

 

http://download2.eurordis.org/rare2030/Rare2030_recommendations.pdf

 

Rare 2030 is a proposal of EU policy recommendations that will bring improved policy and a better future for people living with a rare disease in Europe. This two-year project  was presented to EU Parliament last week with recommendations on the most critical areas needing better policy.

Here you can find information about Rare 2030: https://www.rare2030.eu

 

Please have a look at it and share it widely in your groups and countries. We will need to encourage our EU ministers to support it, so it’s good to learn as much as possible about it.

 

Use Rare Disease Day to start that conversation around you.

 

As they say: “Rare diseases are rare, but rare disease patients are numerous”.[/vc_column_text][/vc_column][/vc_row]

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

💜 We've taken part in the EULAR PARE Conference 2026 in Brussels! And what an interesting opportunity to discuss the future of AI in healthcare!

🌍 Bringing together more than 100 delegates and speakers from across Europe and beyond, the conference explored some of the most important questions surrounding artificial intelligence in rheumatology and patient advocacy.

From the opportunities and risks of AI to health inequalities, accessibility and European health policy, the discussions highlighted why patient perspectives must be part of the conversation.

🤩 We were particularly proud to see Jeanette Andersen, Chair of the Lupus Europe Board, sharing our experience with #LupusGPT in her presentation, “AI as a Partner in Care: Empowering the RMD Community with Information”.

💡 Jeanette explained how #LupusGPT was developed with patients and clinicians to offer free, multilingual access to reliable lupus information based on validated sources.

She also introduced #EasyLupus, which provides the same trusted information in simpler language, highlighting why accessibility must be considered when developing AI tools.

But one of the most important messages from her presentation went beyond technology.

💜 Patient organisations have much more to contribute to AI than simply using tools developed by others.

As Jeanette highlighted, patient organisations bring lived experience, knowledge of unmet needs, trusted information and an understanding of the barriers people face when accessing health information.

Technology alone cannot tell us what patients really need or what makes a tool genuinely useful.

Patients and patient organisations should not simply be users of AI. They should help shape its development.

👏 A big thank you to EULAR PARE for bringing together so many different perspectives and creating space for meaningful discussions about the future of healthcare and patient involvement!
...

💜 Weve taken part

🦋 One of the greatest strengths of patient organisations is the support, understanding and sense of community they offer to people living with lupus. 💜

🇧🇬 A great example comes from Организация на пациентите с ревматологични заболявания, who shared their psychological support initiative at the #LupusConvention!

💜 Launched in December 2025, this pilot project provides a safe and supportive space where participants can share their experiences and discuss the challenges of living with lupus, from fatigue and anxiety to relationships and everyday life.

👥 Led by a clinical psychologist, the group currently brings together six women. The project is expected to run until December 2026, while the organisation explores funding opportunities to continue and expand the initiative.

Thank you to our Bulgarian colleagues for sharing their experience, and congratulations on the amazing job you are doing! ❤️

🌍 This is just one example of the valuable work patient organisations are doing across Europe, often responding to needs that go beyond medical care. We'll share more in the coming days!

💜 Are you living with lupus? You don't have to navigate everything alone! Your national lupus organisation may offer information, support, activities and opportunities to connect with others who understand your experiences.

🔗 Find your national lupus organisation and get in touch:
lupus-europe.org/lupus-members/
...

Image attachment
Image attachment

💜 Young people living with lupus are not only the future of patient advocacy. Their voices matter today!

On 23 and 24 October, LUPUS EUROPE was delighted to be represented at the first 𝗘𝗣𝗙 𝗬𝗼𝘂𝘁𝗵 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟲 in Brussels by Ana Rita Vieira, from the LUPUS EUROPE Youth Group, and Lena Koskina, LUPUS EUROPE's Youth Group Coordinator.

🌍 Organised by European Patients' Forum and its EPF Youth Group, the Congress brought together young patient advocates from across Europe to explore the challenges facing young people living with chronic conditions, from economic uncertainty and climate change to the barriers they encounter when trying to influence healthcare decisions.

🌟 One particularly important question ran through the discussions: 𝗵𝗼𝘄 𝗱𝗼 𝘄𝗲 𝗺𝗼𝘃𝗲 𝗯𝗲𝘆𝗼𝗻𝗱 𝘀𝗶𝗺𝗽𝗹𝘆 𝗴𝗶𝘃𝗶𝗻𝗴 𝘆𝗼𝘂𝗻𝗴 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮 𝘀𝗲𝗮𝘁 𝗮𝘁 𝘁𝗵𝗲 𝘁𝗮𝗯𝗹𝗲, 𝗮𝗻𝗱 𝗲𝗻𝘀𝘂𝗿𝗲 𝘁𝗵𝗲𝘆 𝗵𝗮𝘃𝗲 𝗮 𝗿𝗲𝗮𝗹 𝘀𝗮𝘆 𝗶𝗻 𝘁𝗵𝗲 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗯𝗲𝗶𝗻𝗴 𝗺𝗮𝗱𝗲❓

The conversations also highlighted something easily overlooked: 𝗺𝗲𝗮𝗻𝗶𝗻𝗴𝗳𝘂𝗹 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗶𝗼𝗻 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝘀 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝗮𝗻 𝗶𝗻𝘃𝗶𝘁𝗮𝘁𝗶𝗼𝗻. Young people living with chronic conditions are often balancing their health with education, employment and financial pressures. Advocacy opportunities need to recognise those realities, and not be accessible only to those who can afford the time and resources to participate.

🦋 At LUPUS EUROPE, supporting the Youth Group means actively helping create those opportunities, connecting young advocates with others across Europe and ensuring their perspectives can meaningfully contribute to the work we do.

Young people living with lupus are already advocates, bringing their experiences, ideas and knowledge into conversations that matter.

💜 Thank you to European Patients' Forum and its EPF Youth Group for bringing everyone together, and to Rita and Lena for representing LUPUS EUROPE at this important Congress!
...

💜 Young people li

🔊 Hot off the press!

💜 Treatment adherence is important, complex and multifactorial.

But understanding the importance of treatment adherence is not the same as knowing how to support it in everyday clinical practice.

That’s why, in 2020, EULAR published its Points to Consider for the prevention, screening, assessment and management of nonadherence to treatment in people with rheumatic and musculoskeletal diseases.

But having recommendations is only the first step. How can we ensure they become part of everyday clinical practice?

🤩 An interesting new viewpoint published in EULAR Rheumatology Open, co-authored by Jeanette Andersen, Chair of the Lupus Europe Board, now explores the challenges of putting these recommendations into routine rheumatology care.

The article highlights that nonadherence is not simply a matter of individual patient behaviour. Concerns about treatment, practical difficulties, access to medication, socioeconomic circumstances and communication with healthcare professionals can all play a role.

The authors highlight five key priorities for putting adherence support into routine rheumatology practice:

🔹 Assessment: Identifying adherence behaviours and the barriers behind them.
🔹 Monitoring: Reassessing adherence over time, as it may change throughout the disease course.
🔹 Shared decision-making: Discussing patients’ preferences, expectations and concerns through non-judgemental communication.
🔹 Multidisciplinary care: Involving the wider healthcare team according to individual needs.
🔹 Training: Making adherence support part of rheumatology education and professional development.

💜 The challenge is not the lack of recommendations, but making adherence assessment and support a routine part of rheumatology care.

📖 Read the open-access viewpoint: doi.org/10.1016/j.ero.2026.100261
...

Image attachment
Image attachment
Image attachment
Image attachment
LUPUS EUROPE Uniting people with Lupus throughout Europe
Send